Guer, Melis
Janitzky, Andreas
Schostak, Martin
Funding for this research was provided by:
Universitätsklinikum Magdeburg
Article History
Received: 25 November 2022
Accepted: 20 July 2023
First Online: 8 August 2023
Declarations
:
: MS: Honoraria: Bayer, Merck, Astra Zeneca/MedImmune, Janssen Oncology, Pfizer; Consulting Role: MSD, Astra Zeneca, Bayer, Bristol-Myers Squibb, Pfizer, Ipsen, EDAP TMS, Sanofi, Janssen Oncology, Astellas Pharma; Research Funding: Bristol-Myers Squibb Foundation, Astra zeneca, Ipsen, MSD Oncology, Janssen Oncology, Sanofi, Bayer. AJ: Honoraria: Apogepha, Astellas Pharma, Eisai, EUSA Pharma, Ipsen, Janssen-Cilag, Merck, Novartis, Pfizer, Pierre Fabre, Roche, UOAK Sachsen-Anhalt; Consulting Role: Bayer, Bristol-Myers Squibb, Coloplast, Eisai, EUSA Pharma, Ipsen, Janssen-Cilag, Roche, Pnn Medical A/S. MG: No conflict of interest.
: None.
: None (research did not involve human participants).